Objectives. Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease
|
|
- Clare Simon
- 5 years ago
- Views:
Transcription
1 Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease Erika Berman Rosenzweig, MD Director, Pulmonary Hypertension Center Associate Professor of Clinical Pediatrics (in Medicine) Columbia University Medical Center Has received grant/research support from Actelion, Bayer AG, Eli Lily, Gilead Sciences, GSK, Novartis AG, Pfizer, and United Therapeutics Corporation Has served as a consultant for Actelion, GIlead and United Therapeutics. Objectives Provide a comprehensive review of available targeted oral treatment options for children with PAH Discuss when to consider the use an oral therapy for the treatment of PAH in a pediatric patient Provide a preview of potential future oral therapeutic targets PAH Treatment Goals Fewer/less severe symptoms Improved functional class Improved exercise capacity Improved hemodynamics Prevention of clinical worsening Improved quality of life Improved survival Ability to attend school Ability to participate in non-competitive activities Children 1
2 What Is the Optimal Treatment Strategy? Anticoagulate ± Diuretics ± Oxygen ± Digoxin Oral CCB Sustained Response Yes Continue CCB Positive Negative No LOWER RISK DETERMINANTS OF RISK HIGHER RISK No Clinical evidence of RV failure Yes Gradual Progression of symptoms Rapid II, III WHO class IV Longer (>4 m) 6MWD Shorter (<3 m) Peak VO 2 >1.4 ml/kg/min CPET Peak VO 2 <1.4 ml/kg/min Minimal RV dysfunction RAP <1 mm Hg; CI >2.5 L/min/m 2 Echocardiography Hemodynamics Pericardial effusion, significant RV enlargement/dysfunction; RA enlargement RAP >2 mm Hg; CI <2. L/min/m 2 Minimally elevated BNP Significantly elevated McLaughlin VV et al. J Am Coll Cardiol. 29;53: Acute Vasoreactivity Testing Chronic Oral Adjuvant Therapies in PAH Managing right heart failure Digoxin Variable inotropic effect and use No long-term data; need to balance unproven benefits with known risks Diuretics Most patients need Anticoagulation Recommended in IPAH/HPAH Retrospective adult data only; Need to balance unproven benefits with known risks particularly in active children INR Badesch DB et al. Chest. 24;126:35S-62S. Badesch DB et al. Chest. 27;131: McLaughlin VV et al. J Am Coll Cardiol. 29;53: What Is the Optimal Treatment Strategy? Anticoagulate ± Diuretics ± Oxygen ± Digoxin Positive Acute Vasoreactivity Testing Calcium Channel Blockers Only If acute vasodilator responsive Oral CCB Sustained Response Yes Continue CCB No LOWER RISK DETERMINANTS OF RISK HIGHER RISK No Clinical evidence of RV failure Yes Gradual Progression of symptoms Rapid II, III WHO class IV Longer (>4 m) 6MWD Shorter (<3 m) Peak VO 2 >1.4 ml/kg/min CPET Peak VO 2 <1.4 ml/kg/min Minimal RV dysfunction RAP <1 mm Hg; CI >2.5 L/min/m 2 Echocardiography Hemodynamics Negative Pericardial effusion, significant RV enlargement/dysfunction; RA enlargement RAP >2 mm Hg; CI <2. L/min/m 2 Minimally elevated BNP Significantly elevated Vasodilator Response: Adult Definition Decrease in PAPm by 1 mm Hg Decrease of PAPm to < 4 mm Hg McLaughlin VV et al. J Am Coll Cardiol. 29;53: Sitbon O, et al. Circulation. 25 2
3 Survival in IPAH Long-term CCB Responders Calcium Channel Blockers Only If acute vasodilator responsive Cumulative survival Long-term CCB responders (~5% of acute responders or 6% of IPAH patients) Long-term CCB failure p=.7 Vasodilator Response Decrease in PAPm by 1 mm Hg Decrease of PAPm to < 4 mm Hg. Subjects at risk, n Sitbon O et al. Circulation Years Long-term CCB responders Long-term CCB failure Does this definition identify long term pediatric responders? What about children who start out with PAPm <4mmHg? Sitbon O, et al. Circulation. 25 AVT response in Young Children with resting PAPm < 4: Modification of historical definition Vasodilator Response Decrease in PAPm by 2% An increase or no change in CI Decrease in PVRi or no change in PVRi/SVRi ratio Barst RJ, et al. Circulation 212 REVEAL: Peds CCB patients with AVT available (n=42) Adult definition 22 Modified Peds definition Did not meet AVT criteria Met AVT criteria Barst RJ, et al. Circulation 212 3
4 Pediatric AVT: REVEAL Registry Overall Pediatric Acute response rate for IPAH/HPAH - 35% Of the 22 patients on CCB who were responsive by Barst modified definition, 5 year survival was 1% Of the general REVEAL population 162/216 had AVT available 36/12 (35%) IPAH/FPAH were responders 9/6 (15%) APAH-CHD were responders Barst RJ, et al. Circulation 212 IPAH in Children: Improved Survival with Chronic Calcium Channel Blockade Survival (n=26) (n=18) (n=11) (n=19) (n=6) p=.2 (n=5) 1 2 Years Acute responders Acute nonresponders (n=31) (n=43) Barst, et al. Circ, 1999 Kaplan-Meier curves for survival and treatment success in Acute Responders on CCB: n=31 Why not use CCB s in All Kids? Net Effect not same for all Pulmonary Vasodilation CO Systemic Vasodilation Neg Inotropy CO Yung D et al. Circulation 24;11: Highly variable Influenced by the drug and the disease Risks of getting it wrong: tachycardia, dyspnea, hypotension, syncope, death CCBs should NOT be used empirically 4
5 AVT response in Children: Suggest using modification of historical definition Vasodilator Response Decrease in PAPm by 2% An increase or no change in CI Decrease in PVRi or no change in PVRi/SVRi ratio Barst RJ, et al. Circulation 212 What Is the Optimal Treatment Strategy? Anticoagulate ± Diuretics ± Oxygen ± Digoxin Oral CCB Sustained Response Yes Continue CCB Positive No LOWER RISK DETERMINANTS OF RISK HIGHER RISK No Clinical evidence of RV failure Yes McLaughlin VV et al. J Am Coll Cardiol. 29;53: Gradual Progression of symptoms Rapid II, III WHO class IV Longer (>4 m) 6MWD Shorter (<3 m) Peak VO 2 >1.4 ml/kg/min CPET Peak VO 2 <1.4 ml/kg/min Minimal RV dysfunction RAP <1 mm Hg; CI >2.5 L/min/m 2 Acute Vasoreactivity Testing Echocardiography Hemodynamics Negative Pericardial effusion, significant RV enlargement/dysfunction; RA enlargement RAP >2 mm Hg; CI <2. L/min/m 2 Minimally elevated BNP Significantly elevated Oral Therapies: When are they indicated for children? Monotherapy? Up-front Combination therapy? Add on therapy? Transition off IV/SQ prostanoid therapy?? PAH Determinants of Risk: Where do Oral Therapies fit in? Is a child really ever Lower Risk? LOWER RISK? DETERMINANTS OF RISK HIGHER RISK No Clinical evidence of RV failure Yes Gradual Progression of symptoms Rapid II, III WHO class IV Longer (>4 m) 6MWD Shorter (<3 m) Peak VO 2 >1.4 ml/kg/min CPET Peak VO 2 <1.4 ml/kg/min Minimal RV dysfunction RAP <1 mm Hg; CI >2.5 L/min/m 2 Echocardiography Hemodynamics Pericardial effusion, significant RV enlargement/dysfunction; RA enlargement RAP >2 mm Hg; CI <2. L/min/m 2 Minimally elevated BNP Significantly elevated McLaughlin VV et al. J Am Coll Cardiol. 29 5
6 French Registry: Kaplan-Meier Survival Estimates According to Baseline NYHA Functional Class Survival (%) No. at risk: NYHA I/II NYHA III NYHA IV NYHA I/II 4 NYHA III NYHA IV Time (mo) Combined idiopathic, familial, and anorexigen-associated PAH. Humbert M et al. Circulation. 21;122: French Registry: Kaplan-Meier Survival Estimates According to Baseline 6MWD Survival (%) No. at risk: m m -249 m Time (mo) Combined idiopathic, familial, and anorexigen-associated PAH. Humbert M et al. Circulation Plasma BNP as a Prognostic Indicator in Patients With IPAH Survival rate (%) Follow-up BNP BNP <18 pg/ml p.1 2 BNP 18 pg/ml p Time (mo) By multivariate analysis, higher BNP at follow-up (RR=25.88, p=.243) was an independent predictor of mortality. Nagaya N et al. Circulation. 2;12: ACCF/AHA Consensus PAH Treatment Algorithm Anticoagulate ± Diuretics ± Oxygen ± Digoxin Oral CCB Sustained Response Yes Continue CCB No Positive Lower Risk ERAs or PDE-5 Is (oral) Epoprostenol or Treprostinil (IV) Iloprost (inhaled) Treprostinil (SC, inhaled) Reassess: consider combo-therapy Investigational Protocols Modified from McLaughlin VV et al. J Am Coll Cardiol. 29;53: Acute Vasoreactivity Testing Negative Higher Risk Epoprostenol or Treprostinil (IV) Iloprost (inhaled) ERAs or PDE-5 Is (oral) Treprostinil (SC) Atrial septostomy Lung transplant 6
7 Approved Therapeutic Targets REVEAL: Pediatric Therapies (n=216) Endothelin receptor A Endothelinreceptor antagonists Endothelin Pathway Pre-proendothelin Endothelin-1 Proendothelin Endothelin receptor B Vasoconstriction and proliferation Endothelial cells Nitric Oxide Pathway L-arginine Phosphodiesterase type 5 Nitric Oxide cgmp L-citrulline Exogenous nitric oxide Vasodilation and antiproliferation Endothelial cells Prostacyclin Pathway Arachidonic acid camp Vasodilation and antiproliferation Prostaglandin I 2 Prostacyclin (prostaglandin I 2 ) Prostacyclin derivatives % Therapy Type Phosphodiesterase type 5 inhibitor Smooth muscle cells Smooth muscle cells Prostanoids PDE-5 inh ERAs CCB Humbert M et al. N Engl J Med. 24;351: Barst RJ, et al. Circulation 212 Approved Therapeutic Targets Endothelin receptor A Endothelinreceptor antagonists Endothelin Pathway Pre-proendothelin Endothelin-1 Smooth muscle cells Proendothelin Endothelin receptor B Vasoconstriction and proliferation Endothelial cells Nitric Oxide Pathway L-arginine Phosphodiesterase type 5 Nitric Oxide cgmp L-citrulline Phosphodiesterase type 5 inhibitor Exogenous nitric oxide Vasodilation and antiproliferation Endothelial cells Prostacyclin Pathway Arachidonic acid camp Vasodilation and antiproliferation Prostaglandin I 2 Prostacyclin (prostaglandin I 2 ) Smooth muscle cells Prostacyclin derivatives Humbert M et al. N Engl J Med. 24;351: ERA Therapies Bosentan (21) Dual endothelin receptor ET A /ET B blockade Pivotal trials included children > 12yrs old Indicated for twice daily administration to improve exercise capacity and reduce clinical worsening in WHO FC II-IV PAH patients Ambrisentan (28) Selective ET A receptor antagonist Pivotal trials in adults Indicated for once-daily treatment of PAH to improve exercise capacity and delay clinical worsening in patients with WHO FC II or III symptoms 7
8 Bosentan: 6-MWD (351 and BREATHE-1) Mean change from baseline (m) Study 351 Baseline Week **p<.5 vs baseline; p=.21 vs placebo. Values are mean±sem. Channick RN et al. Lancet. 21;358: Rubin LJ et al. N Engl J Med. 22;346; ** Bosentan (n=21) (n=11) BREATHE-1 Bosentan (n=144) (n=69) p=.2 Baseline Week Event-free (%) Bosentan: Time to Clinical Worsening (BREATHE-1 and EARLY) BREATHE-1 p=.38 Bosentan (n=144) 89% p=.15 Bosentan (n=35) (n=69) (n=13) Time (wk) 63% Time (wk) Adapted from Rubin LJ et al for the BREATHE Study Group. N Engl J Med. 22;346; Galiè N et al. Lancet. 28;371: Patients with no clinical worsening (%) p=.114 Bosentan EARLY Effects of Long-term Bosentan in Children with PAH Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, Barst RJ. JACC. 25 Retrospective case review (2 US centers) 78 pts <18 years with IPAH or APAH Assessed long-term outcomes (up to 2 years) in pediatric PAH patients treated with bosentan Evaluated Adverse events/safety WHO functional class Hemodynamics Survival Hemodynamic Effects of Chronic Bosentan in Pediatric PAH (n=49) Patients on bosentan Baseline Follow-up Change (All patients) n=49 n=49 n=49 PAPm (mmhg) 64 ± 3 57 ± 3-7 ± 2* PVRI (units m2) 2 ± 2 15 ± 2-4 ± 2* Cardiac Index (L/min/m 2 ) 3.8 ± ±.2. ±.2 PCWPm (mmhg) 9 ± 9 ± 1 1 ± 1 RAPm (mmhg) 7 ± 1 7 ± 1 ± 1 p<.5 vs. baseline; paired t-test Mean ± SE Median f/u: 27 days Rosenzweig EB, et al., JACC, 25 8
9 Changes in WHO Functional Class at bosentan initiation and after at least eight weeks of treatment with bosentan Effects of Long-term Bosentan in Children with PAH Improvement in hemodynamics (PAPm, PVRi) Improvement or stabilization of WHO class in 9% patients 1- and 2-year survival: 98% and 91%, respectively Bosentan was well tolerated with efficacy/safety appearing similar in children as reported in adults Rosenzweig, EB. et al. J Am Coll Cardiol 25 Rosenzweig EB, et al., JACC, 25 Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings D. Dunbar Ivy MD, Erika Berman Rosenzweig MD, Jean-Christophe Lemarié, Monika Brand, Daniel Rosenberg PhD, and Robyn J. Barst MD. Am J Cardiol 21. Patient treatment patterns throughout observation period (median observation was 39 months) Retrospective cohort study analyzed outcomes in 86 children with PAH treated with bosentan IPAH/ HPAH (n=36) and APAH (n=5) who started bosentan treatment from May 21 to April 23 in 2 Pediatric Pulmonary Hypertension centers Data collection ended August 26 Ivy DD, et al. Am J Card, 21 9
10 Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings: Results Kaplan-Meier estimates of survival related to baseline PVRi <2 vs>2 Wood units Risk factors significantly associated with survival : PVRi WHO Functional Class Ivy DD, et al. Am J Card, 21 Ivy DD, et al. Am J Card, 21 At 4 years, the Kaplan-Meier estimate of disease progression in patients while on bosentan was 54% with a survival estimate of 82% Long-term efficacy of bosentan in the treatment of PAH in children Hislop AA, Moledina S, Foster H, Schulze-Neick, Haworth SG, Eur Resp Journal, % 5 year retrospective experience using bosentan in pediatric PAH (n=11; IPAH (42), APAH-CHD (59) Evaluated WHO FC,6MW, weight, height Treated for at least 6 months and followed for up to 5 years (2/2-5/9) Ivy DD, et al. Am J Card, 21 1
11 Long-term efficacy of bosentan in the treatment of PAH in children At 3 years 21% of IPAH patients remained on monotherapy Initial improvement in WHO FC and 6MW were sustained over 3 years K-M survival (n=11) 1, 2, 3 and 5 years 96%, 89%, 83%, and 6% Hislop AA, et al, Eur Resp Journal, 211 ERA Therapies Bosentan (21) Dual endothelin receptor ET A /ET B blockade Pivotal trials included children > 12yrs old Indicated for twice daily administration to improve exercise capacity and reduce clinical worsening in WHO FC II-IV PAH patients Ambrisentan (28) Selective ET A receptor antagonist Pivotal trials in adults Indicated for once-daily treatment of PAH to improve exercise capacity and delay clinical worsening in patients with WHO FC II or III symptoms Ambrisentan in PAH: 6MWD (ARIES) 6MWD (m) ARIES-1 1 mg ambrisentan 5 mg ambrisentan Time (wk) p-values are vs placebo. Galiè N et al. Circulation. 28;117: p<.1 p<.1 ARIES-2 5 mg ambrisentan 2.5 mg ambrisentan p< Time (wk) p<.1 Ambrisentan in PAH: Time to Clinical Worsening (ARIES) Event-free (%) ARIES-1 5 mg ambrisentan 2 1 mg ambrisentan 5 and 1 mg ambrisentan Time (wk) Galiè N et al. Circulation. 28;117: ARIES mg ambrisentan 5 mg ambrisentan 2.5 and 5 mg ambrisentan p< Time (wk) 11
12 Clinical safety, efficacy, and pharmacokinetics of ambrisentan therapy in children with pulmonary arterial hypertension Shinichi Takatsuki MD, Erika Berman Rosenzweig MD, Warren Zuckerman MD, Daniela Brady RN, Michelle Calderbank RN, and David Dunbar Ivy MD, Pediatric Pulmonary, 212 (in press) Change in WHO Functional Class between Baseline and treatment with Ambrisentan therapy Retrospective study of 38 pediatric pts at two PH Centers who received ambrisentan as initial (6%) or add on therapy for PAH; 4% transitioned from bosentan Evaluated clinical status (hemodynamics, WHO FC, exercise capacity) and for adverse events. Evaluated pharmacokinetics in a subset of patients (n=16) Takatsuki S, et al. Pediatric Pulmonary, 212 (in press) Ambrisentan: Changes in Clinical Variables Clinical variables N* On bosentan Transition On ambrisentan p value N* Add-on before after p value Kaplan-Meier estimates of survival at 1 year and 2, 3, and 4 years 6 minute walking distance (m) / / / / Brain natriuretic peptide (pg/ml) / / / / Tricuspid regurgitant velocity (m/s) Mean right atrial pressure (mmhg) / / / / / / / / Mean pulmonary arterial pressure (mmhg) Pulmonary vascular resistance index (unitxm 2 ) Pulmonary / systemic vascular index ratio / / / / / / / / /-.3.7+/ /-.8.8+/ Cardiac index (l/min/m 2 ) / / / / Alanine aminotransferase (unit/l) Aspartate aminotransferase (unit/l) / / / / / / / / Total bilirubin (mg/dl) 12.7+/-.9.7+/ /-.4.4+/ Takatsuki S, et al. Pediatric Pulmonary, 212 (in press) IPAH/HPAH 1%, 88%, 88%, and 85% PAH-CHD were 96%, 91%, 87%, and 87%, respectively 12
13 Ambrisentan pharmacokinetics in children appear similar to adults although T ½ is slightly shorter (n=16) mean Cmax mean Tmax mean T ½ mean AUC / ng/ml 3.2+/-2.1 hours 7.6+/-2.6 hours / ng hr/ml Endothelin Receptor Antagonists: Side Effects Nasal congestion Abnormal hepatic function reversible transaminase elevations >3X ULN may require dose adjustments or discontinuations monthly LFTs required for bosentan Edema lower extremity edema may require diuretic adjustment Use requires dual contraceptive methods (hormonal plus barrier) Takatsuki S, et al. Pediatric Pulmonary, 212 (in press) Endothelin Receptor Antagonists in Pediatric PAH ERA s have been shown to be efficacious and safe in adults with PAH In children, data is limited but supportive of similar use for children with PAH Close monitoring of response and for AE s and LFT abnormalities is suggested Approved Therapeutic Targets Endothelin receptor A Endothelinreceptor antagonists Endothelin Pathway Pre-proendothelin Endothelin-1 Smooth muscle cells Proendothelin Endothelin receptor B Vasoconstriction and proliferation Endothelial cells Nitric Oxide Pathway L-arginine Phosphodiesterase type 5 Nitric Oxide cgmp L-citrulline Phosphodiesterase type 5 inhibitor Exogenous nitric oxide Vasodilation and antiproliferation Endothelial cells Prostacyclin Pathway Arachidonic acid camp Vasodilation and antiproliferation Prostaglandin I 2 Prostacyclin (prostaglandin I 2 ) Smooth muscle cells Prostacyclin derivatives Humbert M et al. N Engl J Med. 24;351:
14 Effect of Sildenafil on 6MWD (SUPER) Change In 6MWD (m) Galiè N et al. N Engl J Med. 25;353: mg of sildenafil 4 mg of sildenafil 8 mg of sildenafil p< Week Sildenafil: Incidence of Clinical Worsening (SUPER) (n=7) 2 mg tid (n=69) Sildenafil 4 mg tid (n=67) Event Incidence, n (%) 8 mg tid (n=71) Clinical worsening 7 (1) 3 (4) 2 (3) 5 (7) death 1 (1) 1 (1) 2 (3) hospitalization for PAH 7 (1) 2 (3) 2 (3) 2 (3) initiation of prostacyclin 1 (1) initiation of bosentan 1 (1) 2 (3) p=ns. Clinical worsening defined as death, transplantation, hospitalization for PAH, or initiation of additional therapies for PAH. Galiè N et al for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. N Engl J Med. 25;353: Kaplan-Meier estimates of survival by treatment group in the SUPER-1 study Rubin L J et al. Chest 211;14: Sildenafil Added to Epoprostenol (PACES) Mean 6MWD change from baseline (95% CI), m Baseline Study time (wk) Opposite order than usual practice. Different approach to epo dosing. Most pts on 8 mg TID (not approved). Simonneau G et al. Ann Intern Med. 28;149: Erratum: Ann Intern Med. 29;15:63; 29;151:435. p<.1 No. clinical worsening event (%) p=.2 Epoprostenol + sildenafil Epoprostenol + placebo Baseline Time from randomization (d) Baseline Persons at Risk (Censored), n Day Day Day Day 112 Epo + placebo (1) 116() 111(2) 7(36) Epo + sildenafil () 128(2) 125(2) 78(44) 14
15 Sildenafil in Children with PAH Clinical applications have been based on adult SUPER trials Limited data in pediatrics yet use is widespread In case series, dosing is variable and ranges from.5mg to 2mg/kg po t.i.d/q.i.d. despite lack of pharmacokinetic data Sildenafil Pediatric pharmacokinetic considerations In adults, onset of action 3-12 minutes (delay if taken with fatty foods up to 6 min) Hepatic metabolism (CYP 3A4 and CYP 2C9) Drug interactions CYP3A4 inhibitors (fluconazole, ketoconazole, itraconazole) lead to increase in plasma level CYP3A4 inducers (bosentan) lead to 63% decrease in sildenafil AUC and 5% increase in bosentan AUC Oral solution of sildenafil can be compounded Sildenafil Potential areas of use in Children with PAH To prevent rebound PH during ino weaning In place of NO when unavailable Infants with chronic lung disease Perioperative PAH (e.g. CHD repair) Long-term treatment of IPAH/APAH Including in combination with other targeted agents A Randomized, Double-Blind, -Controlled, Dose- Ranging Study of Oral Sildenafil Citrate in Treatment-Naïve Children with Pulmonary Arterial Hypertension (STARTS 1) Robyn J Barst, D. Dunbar Ivy, Guillermo Gaitan, Andras Szatmari, Andrzej Rudzinski, Alberto E Garcia, BKS Sastry, Tomas Pulido, Gary R Layton, Marjana Serdarevic-Pehar and David L. Wessel, Circulation, 212. The first double blind placebo controlled trial of a targeted PH therapy in children Enrolled 238 treatment naïve children weighing > 8kg Randomized to placebo, low, medium or high dose of sildenafil Data compared from baseline to 16 weeks. Additional data was captured in an extension study STARTS - 2 Barst RJ, et al. Circulation,
16 Sildenafil Dosing in STARTS-1 Sildenafil dose in mg Body wt (kg) Low Medium High > 8 to 2 NA 1 2 >2 to > STARTS studies Primary endpoint was percent change in peak VO2 (combined treatment groups) measured by CPET at 16 weeks All patients were treatment naïve 16 patients >7 yrs old were able to perform exercise test reliably and included in analyses Barst RJ, et al. Circulation, 212 Barst RJ, et al. Circulation, 212 Start 1: -adjusted Percent Change VO 2 Peak Low (n=24) Medium (n=26) High (n=27) Low/Med/High (n=77) p = VO 2 Peak (% change from baseline to Week 16) Comparison to (n=29) with 95% CIs Barst RJ, et al. Circulation, 212 Effects of Sildenafil on PVRI and mpap in Children PVRI Low (n=37) Medium (n=51) High (n=68) L/M/H (n=156) mpap Low (n=39) Medium (n=55) High (n=71) L/M/H (n=165) (Change from baseline to week 16) comparison to placebo (n=52) with 95% CIs (dyne s cm -5 m 2 ) (Change from baseline to week 16) comparison to placebo (n=56) with 95% CIs (mmhg) Barst RJ, et al. Circulation,
17 Sildenafil in Treatment Naïve Pediatric Patients: Results Primary endpoint: Mean % change in peak VO2 was not significant in placebo vs. treatment group (p=.56; all doses) Low dose sildenafil was not effective, but medium and high doses demonstrated improved peak VO2, FC and hemodynamics In STARTS 2 extension if appears that high dose sildenafil was associated with an increase in mortality Sildenafil in Treatment Naïve Pediatric Patients: Conclusions 16 week sildenafil monotherapy was well tolerated in pediatric PAH. Percent change in peak VO2 for the combined sildenafil doses was not significant Improvements in peak VO2, FC and hemodynamics in the medium dose and high doses suggest efficacy Barst RJ, et al. Circulation, 212 Barst RJ, et al. Circulation, 212 Sildenafil in Treatment Naïve Pediatric Patients: Conclusions Effect of Tadalafil on 6MWD (PHIRST) Combined with the STARTS 2 data, the overall profile favors medium dose sildenafil may be most effective with best safety profile Optimal dosing is yet to be determined In Europe, pediatric sildenafil is dosed at 1 mg for patients 1-2kg and 2 mg po tid for patients over 2 kg. Change in 6MWD (m) Tadalafil 2.5 mg Tadalafil 1 mg Tadalafil 2 mg Tadalafil 4 mg p<.1 p<.5 p<.5 Barst RJ, et al. Circulation, Weeks Galiè N et al. Circulation. 29;119;
18 Effect of Tadalafil on Time to Clinical Worsening (PHIRST) Proportion of patients with no clinical worsening Day Week Patients at risk: Tadalafil 2.5 mg Tadalafil 1 mg Tadalafil 2 mg Tadalafil 4 mg Tadalafil 2.5 mg Tadalafil 1 mg Tadalafil 2 mg Tadalafil 4 mg Galiè N et al. Circulation. 29;119; p=.41 PDE-5 Side Effects Nose bleed Headache Dyspepsia Flushing Diarrhea Visual changes Contraindicated with use of nitrates What Is the Optimal Treatment Strategy? Anticoagulate ± Diuretics ± Oxygen ± Digoxin Positive Acute Vasoreactivity Testing ACCF/AHA Consensus PAH Treatment Algorithm Anticoagulate ± Diuretics ± Oxygen ± Digoxin Acute Vasoreactivity Testing Oral CCB Sustained Response Yes Continue CCB Negative No LOWER RISK DETERMINANTS OF RISK HIGHER RISK No Clinical evidence of RV failure Yes Gradual Progression of symptoms Rapid II, III WHO class IV Longer (>4 m) 6MWD Shorter (<3 m) Peak VO 2 >1.4 ml/kg/min CPET Peak VO 2 <1.4 ml/kg/min Minimal RV dysfunction RAP <1 mm Hg; CI >2.5 L/min/m 2 Echocardiography Hemodynamics Pericardial effusion, significant RV enlargement/dysfunction; RA enlargement RAP >2 mm Hg; CI <2. L/min/m 2 Minimally elevated BNP Significantly elevated Oral CCB Sustained Response Yes Continue CCB No Positive Lower Risk ERAs or PDE-5 Is (oral) Epoprostenol or Treprostinil (IV) Iloprost (inhaled) Treprostinil (SC, inhaled) Reassess: consider combo-therapy Investigational Protocols Negative Higher Risk Epoprostenol or Treprostinil (IV) Iloprost (inhaled) ERAs or PDE-5 Is (oral) Treprostinil (SC) Atrial septostomy Lung transplant McLaughlin VV et al. J Am Coll Cardiol. 29;53: Modified from McLaughlin VV et al. J Am Coll Cardiol. 29;53:
19 Initial Therapy: Making the Right Decision Determine the severity of disease Patient preference/ability Try to weigh the data When comparing trials, examine objective baseline characteristics (6MWD, hemodynamics) Low threshold for escalation given the natural history in children Ongoing or Recently Completed Adult Clinical Trials: Novel Oral Therapies FREEDOM-C SERAPHIN Current therapy Added therapy Patients (n) Study duration Primary end point Bosentan and/ or sildenafil Naïve/PDE- 5/PGI/combo Treprostinil oral 3 16 weeks 6MWD Macitentan 742 Event-driven Morbidity/mortality event PATENT Naïve/PGI/ERA Riociguat weeks 6MWD IMPRES 2 current therapies Imatinib 2 24 weeks 6MWD Gilead Stable PAH therapy Cicletanine weeks 6MWD GRIPHON ERA, PDE5 or both Selexipag 67 Event-driven Morbidity/mortality event Novartis Stable PAH therapy Nilotinib 66 6 months PVR Pediatric Oral PAH Therapies: Summary Patients with PAH now have several oral treatment options CCB (only when indicated) ERAs PDE-5 inhibitors Determining when an oral agent is appropriate is still not evidence based and caution and close surveillance is needed New oral treatments are on the horizon and may shape the future of pediatric PAH treatment 19
20 2
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationTreatment of Paediatric Pulmonary Hypertension
Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1 Disclosures I have the following financial relationships
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationSTARTS-1 and -2. Barst R, Ivy DD, et al. Circulation 2012;125:
STARTS-1 and -2 A randomized, double-blind,16 week placebo controlled, dose ranging, parallel group study of oral monotherapy sildenafil in treatment naive children, aged 1-17 years, with pulmonary arterial
More informationTherapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics
1 Therapy Update: ERAs Disclosure Statements Disclosure: Research support from United Therapeutics Most of the medications discussed in this presentation are off-label usage Nidhy Varghese, MD Pulmonary
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationUntreated idiopathic pulmonary arterial hypertension
Congenital Heart Disease Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Delphine Yung, MD; Allison C. Widlitz, MS, PA; Erika Berman Rosenzweig, MD; Diane Kerstein, MD; Greg Maislin,
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationApproach to Pulmonary Hypertension in the Hospital
Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences
More informationEffects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 46, No. 4, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.066
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationIV PGI2 vs. Inhaled PGI2 in chronic lung disease
Inhaled Therapies for PAH Erika Berman Rosenzweig, MD Associate Professor of Clinical Pediatrics (in Medicine) Director, Pulmonary Hypertension Center Columbia University Medical Center Disclosures Has
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationCombination therapy in the treatment of pulmonary arterial hypertension 2015 update
Journal of Rare Cardiovascular Diseases 2015; 2 (4): 103 107 www.jrcd.eu REVIEW ARTICLE Rare diseases of pulmonary circulation Combination therapy in the treatment of pulmonary arterial hypertension 2015
More informationCONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION
CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION MOHAMMED RAFIQUE ESSOP MILPARK HOSPITAL and UNIVERSITY OF THE WITWATERSRAND POINTS FOR DISCUSSION What is the pathogenetic mechanism of PAH? Importance of
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationBosentan for treatment of pulmonary arterial hypertension (I)
KEY PAPER EVALUATION Bosentan for treatment of pulmonary arterial hypertension (I) Sabina A Antoniu University of Medicine and Pharmacy, Clinic of Pulmonary Disease, 62 Costache Negri St, Bl.C2, Sc.A,
More informationTadalafil for the Treatment of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 60, No. 8, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.004
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationIntravenous Therapies for Pulmonary Hypertensive Vascular Disease. Intravenous Treatment for PAH: Past, Present and Future 3/10/2012
Intravenous Therapies for Pulmonary Hypertensive Vascular Disease Robyn J Barst MD Professor Emeritus Columbia University New York, NY March 1 th 212 Presented By: Erika Berman Rosenzweig, MD Dr. Robyn
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationManaging Multiple Oral Medications
Managing Multiple Oral Medications Chris Archer-Chicko, MSN, CRNP PENN Presbyterian Medical Center Arlene Schiro,, CRNP Massachusetts General Hospital Mary Bartlett, CRNP Winthrop University Hospital PH
More informationPrognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies
Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More information*Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
The Relationship between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients with PAH Not Reaching Treatment Goals with Phosphodiesterase 5 Inhibitors James R Klinger,* Raymond
More informationUpdates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS
Updates in Pulmonary Hypertension Pharmacotherapy Ziad Sadik PharmD BCPS Disclosure Information I have no financial relationship to disclose AND I will not discuss off label use and/or investigational
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationClinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16
Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationUpdates on Pulmonary Hypertension Treatment
Updates on Pulmonary Hypertension Treatment Dane Mellgren, PharmD PGY-1 Pharmacy Practice Resident Hennepin County Medical Center 04/27/18 Disclosure I have no disclosures to be made regarding the content
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More information2015 State-of-the-Art Management of Pulmonary Hypertension Based on an Understanding of the Various Etiologies
2015 State-of-the-Art Management of Pulmonary Hypertension Based on an Understanding of the Various Etiologies Vallerie V. McLaughlin, MD, FACC, FAHA Kim A Eagle MD Endowed Professor of Cardiovascular
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationΠνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION. Αναστασία Ανθη
Πανελλήνια Σεμινάρια Ομάδων Εργασίας 2017 k Πνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό Ιατρείο Πνευμ. Υπέρτασης Π.Γ.Ν.
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationUpdate on the Management of Pulmonary Hypertension
Update on the Management of Pulmonary Hypertension Weston Bush, PharmD, BCPS Clinical Pharmacy Specialist, SICU University Hospitals Case Medical Center Disclosures None Treatment (Conventional/Supportive)
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More informationPulmonary Arterial Hypertension (PAH): Emerging Therapeutic Strategies
Pulmonary Arterial Hypertension (PAH): Emerging Therapeutic Strategies Nick H. Kim, M.D. Clinical Professor of Medicine Director, Pulmonary Vascular Medicine Clinical Service Chief, PCCSM La Jolla Pulmonary,
More informationTherapeutic Categories Outlook
Equity Research Health Care Therapeutic Categories Outlook Comprehensive Study February 2017 Alzheimer s Disease Bone Diseases Cardiovascular Central Nervous System Dermatology Diabetes/Obesity Epilepsy
More informationΘεραπεία με βάση τη βαρύτητα ή εξαρχής επιθετική συνδυαστική θεραπεία. Φραντζέσκα Φραντζεσκάκη Πνευμονολόγος-Εντατικολόγος ΠΓΝ «ΑΤΤΙΚΟΝ»
Θεραπεία με βάση τη βαρύτητα ή εξαρχής επιθετική συνδυαστική θεραπεία Φραντζέσκα Φραντζεσκάκη Πνευμονολόγος-Εντατικολόγος ΠΓΝ «ΑΤΤΙΚΟΝ» S.Gaine and V.McLaughlin, Eur Respi Rev 2017;26 Ultimate goal of
More informationΦαρµακοθεραπεία στη Πνευµονική Αρτηριακή Υπέρταση: Αρχική ή διαδοχική συνδυαστική θεραπεία
37 ο Πανελλήνιο Καρδιολογικό Συνέδριο Αθήνα, Οκτώβριος 2016 k Φαρµακοθεραπεία στη Πνευµονική Αρτηριακή Υπέρταση: Αρχική ή διαδοχική συνδυαστική θεραπεία Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό
More information2012 CADTH Symposium. April 2012
2012 CADTH Symposium Using Mixed Treatment Comparisons to compare Oral Treatments for Pulmonary Arterial Hypertension and Inform Policy Decisions by a Public Drug Plan April 2012 Objective of this Presentation
More informationTreprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan
CHEST Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationWhere are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA
Where are we now in the longterm management of PAH and CTEPH? Hits and misses of medical treatment Hap Farber Boston University School of Medicine, Boston, USA Monday, 28 September ERS International Congress
More informationMedical Therapy for Pulmonary Arterial Hypertension* Updated ACCP Evidence-Based Clinical Practice Guidelines
CHEST Clinical Practice Guidelines Medical Therapy for Pulmonary Arterial Hypertension* Updated ACCP Evidence-Based Clinical Practice Guidelines David B. Badesch, MD, FCCP; Steven H. Abman, MD; Gerald
More informationRaymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M.
http://www.jhltonline.org Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled
More informationPulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationGeneral awareness of the rare and devastating
Eur Respir Rev 2010; 19: 118, 331 339 DOI: 10.1183/09059180.00008510 CopyrightßERS 2010 REVIEW Issues related to the management and therapy of paediatric pulmonary hypertension I. Schulze-Neick* and M.
More informationMAURICE BEGHETTI, MARIUS M. HOEPER, DAVID G. KIELY, JOERN CARLSEN, BARBARA SCHWIERIN, ELEANOR S. SEGAL, AND MARC HUMBERT
0031-3998/08/6402-0200 PEDIATRIC RESEARCH Copyright 2008 International Pediatric Research Foundation, Inc. Vol. 64, No. 2, 2008 Printed in U.S.A. Safety Experience With Bosentan in 146 Children 2 11 Years
More informationIdentifying Appropriate Treatment & Management Strategies in Pulmonary Arterial Hypertension
Identifying Appropriate Treatment & Management Strategies in Pulmonary Arterial Hypertension Harold I. Palevsky, M.D. Perelman School of Medicine of the University of Pennsylvania Penn Presbyterian Medical
More informationUpdate on pulmonary HTN
Update on pulmonary HTN Feras Bader, MD, MS, FACC Associate Professor of Medicine- Cardiology University of Utah School of Medicine Director, Advanced Heart Failure and Transplant Program Dabbous Cardiac
More informationSotatercept PULSAR Phase 2 PAH Webinar. March 28, 2018
Sotatercept PULSAR Phase 2 PAH Webinar March 28, 2018 Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY S STRATEGY, FUTURE PLANS and prospects,
More informationThe US REVEAL Registry
Pulmonary Hypertension: Lessons from Contemporary Registries The US REVEAL Registry ESC August 30, 2010 Dave Badesch, MD University of Colorado Disclosures Dr. Badesch has received grant/research support
More informationSATELLITE SYMPOSIUM OF MSD. sgc Stimulation for the treatment of PH. Real life management of PAH: case presentation
SATELLITE SYMPOSIUM OF MSD sgc Stimulation for the treatment of PH Real life management of PAH: case presentation Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflict of
More informationDrug Class Monograph. Policy/Criteria:
Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),
More informationEfficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children
Circ J 2007; 71: 1785 1790 Efficacy and Limitations of Continuous Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension in Japanese Children Tomotaka Nakayama, MD; Hiromitsu Shimada,
More informationClass Update with New Drug Evaluation: Drugs for Pulmonary Arterial Hypertension
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLong-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Eur Respir Rev 2009; 18: 114, 253 259 DOI: 10.1183/09059180.00003109 CopyrightßERSJ Ltd 2009 REVIEW Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
More informationComparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry
nazzareno.galie@unibo.it Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry Nazzareno Galiè, MD, FESC, FRCP (Hon), DIMES 2 Comprehensive clinical classification
More informationPharmacotherapy Timeline. Current Challenges. Findings and Scope of Problem. Evaluating Prostacyclin Safety
Major Issues and Challenges of Hospital Pharmacists When Managing Patients with James C. Coons, PharmD, BCPS (AQ-Cardiology) Associate Professor University of Pittsburgh School of Pharmacy Department of
More informationWednesday, April 25 Screening Diagnosis and Treatment of PAH: An Overview
Wednesday, April 25 Screening Diagnosis and Treatment of PAH: An Overview Kerri Akaya Smith, MD Screening, Diagnosis, and Treatment of Pulmonary Arterial Hypertension (PAH): An Overview New Jersey Association
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationThe challenges in paediatric pulmonary arterial hypertension
REVIEW PULMONARY ARTERIAL HYPERTENSION The challenges in paediatric pulmonary arterial hypertension Maurice Beghetti 1 and Rolf M.F. Berger 2 Affiliations: 1 Paediatric Cardiology Unit, Children s University
More informationThe need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension
REVIEW 6MWD IN PAH TRIALS The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension Sean Gaine 1 and Gérald Simonneau 2 Affiliations: 1 National Pulmonary Hypertension
More informationPulmonary hypertension; does gender matter?
Pulmonary hypertension; does gender matter? Nazzareno Galiè Istituto di Cardiologia Università di Bologna nazzareno.galie@unibo.it Galiè N et al. European Heart Journal (2009) 30, 2493 2537 Pulmonary Hypertension
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Adcirca) Reference Number: HIM.PA.SP23 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important
More informationPulmonary Hypertension: We have come a Long Way
Pulmonary Hypertension: We have come a Long Way Shelley Shapiro M.D. Ph.D Pulmonary Hypertension Program 9001.01 1 2 Disclosures Grant Support Gilead, United Therapeutics, Actelion, GeNO, Medtonics, Bellerphon,
More informationΠνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ
Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ PH is defined as PAPm 25 mm Hg at rest The general definition of PH remains unchanged Most of the relevant epidemiological and therapeutic studies have used the 25 mm
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil, 20mg (as citrate) tablets (Revatio ) No. (596/10) Pfizer Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 10/1/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationPulmonary Hypertension: Follow-up in adolescence and adults
Pulmonary Hypertension: Follow-up in adolescence and adults Helmut Baumgartner Westfälische Wilhelms-Universität Münster Adult Congenital and Valvular Heart Disease Center University of Muenster Germany
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More informationThe Circle of New Life for Pulmonary Hypertension Patients: Where does Palliative Care have a role in the new treatment era?
The Circle of New Life for Pulmonary Hypertension Patients: Where does Palliative Care have a role in the new treatment era? { Kenneth Presberg, MD Professor of Medicine Director, PHA Comprehensive Pulmonary
More informationClinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (all ages)
Clinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (all ages) NHS England Reference: 170065P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationWhat Surgeons Need to Know About. Pulmonary Arterial Hypertension
What Surgeons Need to Know About Pulmonary Arterial Hypertension David B. Badesch, MD Professor of Medicine University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch
More informationBeyond a single pathway: combination therapy in pulmonary arterial hypertension
REVIEW PULMONARY ARTERIAL HYPERTENSION Beyond a single pathway: combination therapy in pulmonary arterial hypertension Olivier Sitbon 1,2,3 and Sean Gaine 4 Affiliations: 1 Univ. Paris-Sud, Université
More informationTARGETED TREATMENTS FOR PHVD SESSION 7: THERAPY UPDATE
TARGETED TREATMENTS FOR PHVD SESSION 7: THERAPY UPDATE Antagonists Endothelin Receptors (ERA) Prostacyclins Epoprostenol Treprostinil Iloprost Dra. Maria Jesús del Cerro Pediatric Pulmonary Hypertension
More information